本文選題：膿毒癥 + 心肌損傷��； 參考：《實(shí)用醫(yī)學(xué)雜志》2016年23期

【摘要】：目的:觀察心型脂肪酸結(jié)合蛋白(H-FABP)和可溶性CD14亞型(Presepsin)在丹參川芎嗪治療膿毒癥心肌損傷患者中的變化及意義。方法:114例膿毒癥心肌損傷患者隨機(jī)分成對(duì)照組和治療組,對(duì)照組給予常規(guī)治療,治療組在對(duì)照組基礎(chǔ)上加丹參川芎嗪。患者治療前及治療6 h、3 d,檢測(cè)H-FABP、Presepsin、肌鈣蛋白I(cTnI)及N-末端腦鈉肽前體(NT-proBNP)的變化,觀察治療前后LVEF、SOFA評(píng)分、主要心臟不良事件(MACE)發(fā)生率及28 d病死率。結(jié)果:治療6 h,治療組H-FABP、Presepsin、cTnI和NT-proBNP低于對(duì)照組(P0.05),兩組H-FABP、cTnI和NT-proBNP高于治療前,Presepsin低于治療前(P0.05)。治療3 d,兩組cTnI和NT-proBNP較治療6 h升高,Presepsin較治療6 h降低(P0.05),對(duì)照組Presepsin、cTnI和NT-proBNP高于治療組(P0.05)。治療組治療后SOFA評(píng)分、LVEF、累計(jì)MACE發(fā)生率和28 d病死率低于對(duì)照組(P0.05)�；颊逪-FABP與SOFA評(píng)分呈正相關(guān)(P0.05)。結(jié)論:丹參川芎嗪能降低患者H-FABP、Presepsin、cTnI和NT-proBNP,改善LVEF,降低28 d病死率,減少M(fèi)ACE發(fā)生,為指導(dǎo)臨床治療提供依據(jù)。
[Abstract]:Aim: to observe the changes and significance of cardiac fatty acid binding protein (H-FABP) and soluble CD14 subtype presepsin in the treatment of septic myocardial injury with Salvia miltiorrhiza Ligustrazine. Methods 114 patients with septic myocardial injury were randomly divided into control group and treatment group. The control group was treated with routine therapy, and the treatment group was treated with salvia miltiorrhiza ligustrazine on the basis of control group. The changes of H-FABPP-Presepsin, cardiac troponin I cTnI and NT-proBNPs were detected before and after treatment. The LVEFSFA scores, the incidence of major adverse cardiac events (MACEE) and the fatality rate of 28 days were observed before and after treatment. Results: at 6 h after treatment, the levels of H-FABPnI and NT-proBNP in the treatment group were lower than those in the control group (P 0.05), and the levels of H-FABPnI and NT-proBNP in the two groups were higher than those in the pre-treatment group (P 0.05). On the 3rd day of treatment, cTnI and NT-proBNP in both groups were significantly higher than those in the treatment group at 6 h. The levels of presepsin cTnI and NT-proBNP in the control group were significantly higher than those in the treatment group at 6 h after treatment, and the levels of P0.05G in the control group were higher than those in the control group. After treatment, the SOFA score, cumulative MACE incidence and fatality rate in the treatment group were lower than those in the control group (P 0.05). There was a positive correlation between H-FABP and SOFA score (P 0.05). Conclusion: Salvia miltiorrhiza tetramethylpyrazine can reduce the H-FABPP-presepsinsinsinsinsintosine cTnI and NT-proBNPs, improve LVEF, reduce the fatality rate of 28 days, reduce the incidence of MACE, and provide the basis for guiding clinical treatment.
【作者單位】： 河北醫(yī)科大學(xué)附屬哈勵(lì)遜國(guó)際和平醫(yī)院急救醫(yī)學(xué)部;河北醫(yī)科大學(xué)附屬哈勵(lì)遜國(guó)際和平醫(yī)院重癥醫(yī)學(xué)科;
【基金】：衡水市科學(xué)技術(shù)研究與發(fā)展計(jì)劃項(xiàng)目(編號(hào):15019)
【分類(lèi)號(hào)】：R459.7;R542.2

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 蘭珍;;丹參川芎嗪治療早期糖尿病腎病的療效及對(duì)炎性因子的影響[J];時(shí)珍國(guó)醫(yī)國(guó)藥;2013年07期

2 高慧琴;;丹參川芎嗪輔助治療慢性肺源性心臟病療效觀察[J];中國(guó)保健營(yíng)養(yǎng);2012年22期

3 祝偉忠;丁毅鵬;;丹參川芎嗪治療急性冠脈綜合征76例臨床觀察[J];中國(guó)熱帶醫(yī)學(xué);2009年07期

4 張旭;江秀龍;雷惠新;;丹參川芎嗪治療急性腦梗死的療效觀察[J];中國(guó)實(shí)用內(nèi)科雜志;2009年S2期

5 怓丹陽(yáng);韓云麗;楊冠英;楊秀蘭;;丹參川芎嗪治療特發(fā)性肺間質(zhì)纖維化86例療效分析[J];黑龍江醫(yī)藥;2010年01期

6 趙巖;;丹參川芎嗪治療急性腦血栓效果觀察[J];家庭醫(yī)藥(醫(yī)藥論壇);2010年04期

7 雷明君;馮蘭珍;董耀;;丹參川芎嗪聯(lián)合圍刺法治療帶狀皰疹后遺神經(jīng)痛40例[J];甘肅中醫(yī);2010年07期

8 趙淑仙;;丹參川芎嗪治療慢性肺心病臨床觀察[J];臨床醫(yī)藥實(shí)踐;2010年21期

9 齊斌;佟鐵壁;;丹參川芎嗪治療糖尿病合并冠心病的臨床觀察[J];中國(guó)社區(qū)醫(yī)師(醫(yī)學(xué)專(zhuān)業(yè));2011年34期

10 劉權(quán)紅;李詩(shī)娟;;丹參川芎嗪的臨床應(yīng)用進(jìn)展與不良反應(yīng)研究[J];北方藥學(xué);2012年09期

相關(guān)會(huì)議論文 前1條

1 譚q，

本文編號(hào)：1926632